大健康：Neuralink放量在即，国产脑机接口有望加快注册

Group 1: Neuralink Developments - Neuralink plans to increase brain-computer interface (BCI) output in 2026, transitioning to nearly fully automated surgeries[3] - As of January 5, 2026, the Wande BCI Index rose by 10.54%, with companies like Sanbo Neuroscience and Meihua Medical hitting the daily limit[3] - Neuralink aims to exceed 25,000 electrodes by 2028, expanding applications to treat mental disorders and integrating with AI[3] Group 2: Policy and Market Support - Multiple government departments in China are supporting BCI development, with the National Healthcare Security Administration including BCI in medical insurance as of March 2025[3] - The "14th Five-Year Plan" lists BCI as one of the six future industries, aiming for significant breakthroughs by 2027[3] - As of December 2025, the BCI sector in China has seen 24 financing rounds, totaling over 5 billion yuan, with a record single financing of 350 million yuan[3] Group 3: Clinical and Commercial Progress - Domestic BCI projects are moving from exploration to clinical stages, with significant trials completed in 2025[3] - The first long-term invasive BCI clinical trial in China was completed in March 2025, marking a milestone in the field[3] - Companies like Sanbo Neuroscience and Meihua Medical are highlighted as key players in the BCI industry, with potential for accelerated commercialization[3]